Athersys, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • ATHX
  • 1d-14.47%
  • 1w-14.47%
  • 1m-53.90%
  • 1y-99.54%
ATH
  • ATH Price$212.50
  • ATH Date2007-07-12
  • % since ATH-100.00%
  • % to ATH3,269,130.77%
ATL
  • ATL Price$0.00570000
  • ATL Date2024-01-11
  • % from ATL14.04%
  • Last Low Price$0.0057
  • Last Low Date2024-01-11
  • % From Last Low14.04%
IPO
  • IPO Price$5.25
  • % Current ROI USD-99.88%
  • ATH Price$212.50
  • % ROI ATH 372,807,017.54%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="ATHX"]

Key Data [addtoany]

Current price $0.0065
Sector Healthcare
Industry Biotechnology
Today's High/Low $0.0095/$0.0065
Volume 135,467.00
Previous Close $0.0076
52 Week High/Low $1.59/$0.0045
Market Cap 833,203.00
P/E Ratio 0
Forward P/E 1 Yr. $0.86
Earnings Per Share(EPS) $0
Annualized Dividend $0
$0.0065
[addtoany]

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine.
Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers.
It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs.
The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity